Transcode Therapeutics, Inc.
RNAZ Nasdaq
SEC CIK 1829635
Follow Transcode Therapeutics
Weekly email: filings, results
Net income
−$107.4M
−2111.3% vs same quarter last year
EPS, diluted
−$9.36
−60.8% vs same quarter last year
Operating cash flow
−$7.7M
−87.7% vs same quarter last year
Operating income
−$109.7M
−2304.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$34.7M |
| FY24 | −$16.8M |
| FY23 | −$18.5M |
| FY22 | −$17.6M |
| FY21 | −$6.8M |
| FY20 | −$2.3M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$19.5M |
| FY24 | −$13.4M |
| FY23 | −$18.1M |
| FY22 | −$15.9M |
| FY21 | −$5.5M |
| FY20 | - |
| FY19 | - |